Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research> CLSA Raises Sinopharm (01099.HK) TP to HKD25, Maintains Outperform
Recommend 2 Positive 3 Negative 0 |
||||
|
||||
|
CLSA published a research report stating that Sinopharm (01099.HK)'s results last year were in line with expectations. Revenue in 4Q rose 1.1% YoY, while gross margin and operating profit margin narrowed by 0.62 ppts and 0.71 ppts, respectively. Benefiting from improved financial leverage and reduced finance costs, net profit still increased 4.4% YoY. The broker believes Sinopharm's profits will remain under pressure, and lowered its revenue forecasts for 2026 and 2027 by 3% and 5.6%, respectively, while cutting net profit forecasts by 4.2% and 7%. However, based on an unchanged target price-to-earnings ratio of 8x, it raised the TP from HKD24.5 to HKD25 and maintained an Outperform rating. (sl/da) This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. Auto-translated by AI AASTOCKS Financial News |
||||
Copied to Clipboard
 |
||||
